@Article{Huang2017,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="21",
number="1",
year="2017",
title="S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature",
abstract="Hepatocellular carcinoma (HCC) is the most common liver neoplasm worldwide. Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other fluoropyrimidines against HCC with DPD activity. This systematic review was aimed to assess the efficacy and safety of S-1 for treatment of advanced HCC.  PubMed, the Cochrane Library, EMBA-  SE, and ClinicalTrials.gov were searched using the terms “Hepatocellular Carcinoma” or “HCC” or “Hepatoma” or “Liver cancer” and ‘‘S-1’’. Outcomes of main interest included overall survival (OS) and toxicities.  We identified four studies of S-1 treatment alone from 1059 references, including a total of 272 patients. There were two original articles and two conference abstracts. The percentage of male patients ranged from 88 to 91.3% and median age ranged from 59 to 70 years. Median OS ranged from 8.6 to 16.5 months. The incidences of toxicity of more than 50% were thrombocytopaenia and fatigue. According to the original description, toxicities were acceptable.  The current evidence from the available clinical studies suggests that S-1 may be an effective and tolerable treatment for advanced HCC. Further clinical studies are warranted to further investigate this treatment option.",
author="Huang, Wu-Kui
and You, Li-na
and Yang, Shu-Fa
and Liu, Deng-Yao
and Liu, Mo
and Fan, Xi-Wen",
pages="16--20",
doi="10.5114/wo.2017.66653",
url="http://dx.doi.org/10.5114/wo.2017.66653"
}